Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...

Pfizer’s Takeda-partnered blood cancer drug Adcetris (brentuximab vedotin) has been approved by the US Food and Drug ...

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...

The US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Adcetris ...

NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with $63.6 billion in annual revenue and an impressive 74% gross profit margin, has announced the U.S. Food and Drug Administration's ...

Patients with metastatic cancer had better quality of life, clinical outcomes, and sense of well-being when they regularly ...

Pfizer Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application ...

The Japanese pharma has been building a presence in oncology over the last few years through products such as its Adcetris (brentuximab vedotin), and its $5.2 billion acquisition of Ariad at the ...

Migraine med Nurtec (rimegepant), the antibody-drug conjugate Adcetris (brentuximab vedotin), as well as Ibrance (palbociclib) and Xeljanz (tofacitinib) are going up in price between 3% and 5%.